NIMBUS APOLLO
Previously a sub-organization of Nimbus Therapeutics, the Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. NDI-010976 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2016 and Phase 1 data for the compound will be presented next month during an oral session at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).
NIMBUS APOLLO
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.nimbustx.com
Total Employee:
11+
Status:
Active
Contact:
857-999-2009
Email Addresses:
[email protected]
Total Funding:
43 M USD
Similar Organizations
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Investors List
Lightstone Ventures
Lightstone Ventures investment in Series B - Nimbus Apollo
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Nimbus Apollo
Official Site Inspections
http://www.nimbustx.com
- Host name: 145.205.196.104.bc.googleusercontent.com
- IP address: 104.196.205.145
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Nimbus Apollo"
About - Nimbus Therapeutics
At Nimbus, our mission is to develop breakthrough medicines for patients through precision small molecule design. We pride ourselves on our nimbleness, our expertise, our focus on …See details»
Culture & Careers - Nimbus Therapeutics
Nimbus is a private company located in Boston, MA with a passionate, talented, multidisciplinary team of “Nimbi.” United by a shared mission to develop breakthrough medicines for patients through precision small molecule design, …See details»
Our Approach - Nimbus Therapeutics
We deploy a range of technologies, including X-ray crystallography and cryo-electron microscopy (cryo-EM) to generate atomic-resolution structural data on our targets — in some cases, for …See details»
Nimbus Therapeutics - Crunchbase Company Profile
View contacts for Nimbus Therapeutics to access new leads and connect with decision-makers. Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical-stage company.See details»
Nimbus Therapeutics - LinkedIn
Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets...See details»
Nimbus Therapeutics - MassBio
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse …See details»
Nimbus Apollo - Crunchbase Company Profile & Funding
Previously a sub-organization of Nimbus Therapeutics, the Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis …See details»
Nimbus Therapeutics - PitchBook
Developer of small molecule compounds designed to discover medicines and transform drug development. The company's platform focuses on metabolic diseases, cancer, and immune-inflammatory disorders and develops selective …See details»
Science - Nimbus Therapeutics
Nimbus is a “science first” biotech company. Our target selection process, one of our most crucial scientific endeavors, is driven by compelling evidence linking molecular targets to human …See details»
Takeda to Acquire Nimbus Therapeutics’ Highly …
Dec 13, 2022 · NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.See details»
Nimbus Therapeutics Appoints Erin Cowhig as Chief People Officer
Oct 19, 2020 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug …See details»
Nimbus Therapeutics Announces Expansion of Its Drug
Jun 8, 2020 · These preclinical programs — AMPKβ2 (AMP-activated protein kinase, β2 subunit), CTPS1 (CTP synthase 1), Cbl-b (Cbl proto-oncogene B), and WRN (Werner syndrome ATP …See details»
Peter J. Tummino - Chief Scientific Officer at Nimbus ... - The Org
Dr. Peter Tummino is Chief Scientific Officer of Nimbus. Prior to joining Nimbus, Peter was Vice President and Global Head of Lead Discovery in Discovery Sciences at Janssen, the Johnson …See details»
Nimbus Therapeutics - Overview, News & Similar companies
Nimbus Therapeutics contact info: Phone number: (857) 999-2009 Website: www.nimbustx.com What does Nimbus Therapeutics do? Nimbus Therapeutics is a clinical-stage, structure-based …See details»
2024 - Nimbus Therapeutics
BOSTON, Mass. — November 7, 2024 — Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for …See details»
Anagenex and Nimbus Announce a Multi-Target Collaboration to …
Through this multi-target collaboration, the companies will apply Anagenex’s AI driven parallel biochemistry platform to generate billions of experimentally measured datapoints for each of …See details»
Erin Cowhig - Chief People Officer at Nimbus Therapeutics - The Org
Erin Cowhig is Chief People Officer of Nimbus Therapeutics. Before joining the team, Erin was Vice President of Human Resources at Vertex Pharmaceuticals. She was responsible for HR …See details»
Reflecting on 15 Years of Innovation at Nimbus Therapeutics
Oct 14, 2024 · Over the past 15 years, Nimbus has grown and changed in many ways, but our core DNA remains the same. We’re a science-first, patient-focused, values-guided biotech. …See details»
Anagenex and Nimbus Announce a Multi-Target ... - Business Wire
Dec 18, 2023 · Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI), will work closely with Nimbus to discover …See details»
NVD - CVE-2024-53976
2 days ago · A lock or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. NVD MENU Information Technology Laboratory …See details»